Kezar Life Sciences Inc (NASDAQ:KZR) — Market Cap & Net Worth
Market Cap & Net Worth: Kezar Life Sciences Inc (KZR)
Kezar Life Sciences Inc (NASDAQ:KZR) has a market capitalization of $1.26 Million ($1.26 Million) as of September 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30543 globally and #6210 in its home market, demonstrating a 17.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kezar Life Sciences Inc's stock price $0.17 by its total outstanding shares 7387701 (7.39 Million). Also see KZR total assets for a full breakdown of the balance sheet.
Kezar Life Sciences Inc Market Cap History: 2018 to 2026
Kezar Life Sciences Inc's market capitalization history from 2018 to 2026. Data shows change from $1.74 Billion to $1.26 Million (-57.11% CAGR). Also see KZR cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Kezar Life Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.00% | #899 of 976 |
|
NASDAQ Composite
IXIC
|
$42.16 Trillion | 0.00% | #2853 of 3165 |
Weight: Kezar Life Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kezar Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kezar Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Kezar Life Sciences Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
10.00x
Kezar Life Sciences Inc's market cap is 10.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $69.99 Million | $7.00 Million | -$101.87 Million | 10.00x | N/A |
Competitor Companies of KZR by Market Capitalization
Companies near Kezar Life Sciences Inc in the global market cap rankings as of September 26, 2026. Review KZR intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kezar Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #333 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $61.49 Billion USD ( AU$86.90 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $522.38 |
| #333 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $796.02 |
| #450 | CSL Ltd | AU:CSL | $61.49 Billion | AU$179.12 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $194.82 |
Kezar Life Sciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Kezar Life Sciences Inc's market cap moved from $1.74 Billion to $ 1.26 Million, with a yearly change of -57.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.26 Million | -97.30% |
| 2025 | $46.47 Million | -6.40% |
| 2024 | $49.65 Million | -29.07% |
| 2023 | $69.99 Million | -86.54% |
| 2022 | $520.09 Million | -57.89% |
| 2021 | $1.24 Billion | +220.31% |
| 2020 | $385.64 Million | +30.17% |
| 2019 | $296.25 Million | -83.01% |
| 2018 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 25th, 2026 the market cap of Kezar Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.26 Million USD |
| MoneyControl | $1.26 Million USD |
| MarketWatch | $1.26 Million USD |
| marketcap.company | $1.26 Million USD |
| Reuters | $1.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more